About the Executive Team

Rahul Singhvi, Sc.D., MBA

Managing Directorr

Dr. Rahul Singhvi is the Managing Director of G-Con, LLC and Caliber Biotherapeutics, LLC. He is a business leader in the biotechnology industry and has served in senior leadership roles in both small and large companies. Until April 2011, he was the President & CEO of Novavax, Inc (Nasdaq: NVAX), a publicly traded development stage vaccine company. During his tenure at Novavax, he transformed Novavax from a distressed specialty pharmaceutical company into a premier vaccine development company and increased its valuation from $35M to $300M. Under his leadership, the Company developed a robust pipeline of clinical and preclinical stage vaccine candidates against influenza, respiratory syncytial virus (RSV), and other infectious diseases. Prior to joining Novavax, Dr. Singhvi served in a number of R&D and manufacturing roles at Merck & Co. At Merck, he co-led the varicella-zoster virus vaccine project team that oversaw the development of ProQuad®(MMRV), Varivax®III (refrigerator stable chickenpox vaccine), and Zostavax® (Shingles vaccine).

Dr. Singhvi is the founder of Axella Solutions, LLC, a strategic advisory firm and serves on the Board of Directors of Immunocellular Therapeutics (NYSE: IMUC), and Ancora Pharmaceuticals (private).

Dr. Singhvi graduated as the top ranked chemical engineer from IIT, Kanpur, India and obtained both his M.S. and Sc.D. degrees in chemical engineering from MIT. He received his MBA degree from the Wharton School of the University of Pennsylvania where he graduated as a Palmer Scholar.

Dr. Singhvi was named one of the most influential Marylanders in the healthcare field by The Daily Record in 2010. During the same year, Novavax was named one of the ten most innovative companies in the biotechnology industry by Fast Company magazine. Dr. Singhvi has served as a member of the Clinton Global Initiative and currently serves on the Board of Directors of Immunocellular Therapeutics (NYSE: IMUC), and Ancora Pharmaceuticals (private).

Dr. Singhvi graduated as the top ranked chemical engineer from IIT, Kanpur, India and obtained both his M.S. and Sc.D degrees in chemical engineering from MIT. He also received an MBA degree from the Wharton School of the University of Pennsylvania where he graduated as a Palmer Scholar.

Barry Holtz

R. Barry Holtz, Ph.D.

Chief Science and Technology Officer

Dr. Holtz was the Senior Vice President of Biopharmaceutical Development for Large Scale Biology Corporation (LSBC) for 15 years and was an integral member of the management team that successfully took the company from a start-up to a publicly-traded company. Dr. Holtz was responsible for the product development, long-term regulatory strategy, and clinical development and manufacturing compliance of the company’s proprietary therapeutics portfolio. He has extensive expertise in providing consulting services to the biopharmaceutical development and manufacturing industry including the design, validation, and quality systems development for personalized cancer therapies and other biologics. Dr. Holtz has held research management positions at Foremost-McKesson and was on the faculty of Ohio State University. He received his Ph.D. at Pennsylvania State University and was an NSF Postdoctoral Fellow at Scripps Institution of Oceanography. Dr. Holtz has been awarded 23 U.S. patents and has published more than 50 scientific papers. He was awarded the Pennsylvania State University, Outstanding Alumni Award in 2003.